SCHEMBL7436876

SCHEMBL7436876

O=C(Cl)c1cc(Br)ccn1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.68
KDM4E B2RXH2 4/20 0.68
SMN1; SMN2 Q16637 2/20 0.68
GRM5 P41594 1/20 0.43
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CTDSP1 Q9GZU7 1/20 0.40
MAPT P10636 4/20 0.39
KDM6B O15054 1/20 0.39
TET3 O43151 1/20 0.39
KDM4A O75164 1/20 0.39
BBOX1 O75936 1/20 0.39
KDM5A P29375 1/20 0.39
KDM5C P41229 1/20 0.39
ASPH Q12797 1/20 0.39
KDM4D Q6B0I6 1/20 0.39
TET2 Q6N021 1/20 0.39
ALKBH5 Q6P6C2 1/20 0.39
KDM7A Q6ZMT4 1/20 0.39
KDM8 Q8N371 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31514843 1.00 ALDH1A1 (0.68) ALDH1A1KDM4ESMN1; SMN2GRM5MEN1
SCHEMBL100727 0.81 KDM4E (1.00) ALDH1A1KDM4ESMN1; SMN2GRM5MAPT
SCHEMBL5700497 0.79 ALDH1A1 (0.68) ALDH1A1KDM4ESMN1; SMN2GRM5MEN1
SCHEMBL30141515 0.79 KDM4E (0.68) ALDH1A1KDM4ESMN1; SMN2GRM5MAPT
Hydrochloric Acid SCHEMBL11679600 0.79 KDM4E (0.96) ALDH1A1KDM4ESMN1; SMN2GRM5MAPT
SCHEMBL786245 0.79 KDM4E (0.68) ALDH1A1KDM4ESMN1; SMN2GRM5MAPT
SCHEMBL29478760 0.79 ALDH1A1 (0.68) ALDH1A1KDM4ESMN1; SMN2GRM5MEN1
SCHEMBL11679598 0.79 ALDH1A1 (0.61) ALDH1A1KDM4ESMN1; SMN2GRM5MEN1
SCHEMBL9772775 0.78 ALDH1A1 (0.66) ALDH1A1KDM4ESMN1; SMN2GRM5MEN1
Lithium Ion SCHEMBL31704468 0.78 KDM4E (0.66) ALDH1A1KDM4ESMN1; SMN2GRM5MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024158698-A1 NOVEL F-ATPASE HYDROLASE INHIBITORS LUCY THERAPEUTICS, INC. (US) 2024-08-02 WO disclosed
CN-115433203-A Amine fluorinated curcumenol derivative compound and application and preparation method thereof 华东理工大学 2022-12-06 CN disclosed
CN-108191761-B Heterocyclic compound and organic light-emitting device using the same LT素材株式会社 2021-12-21 CN disclosed
CN-111712490-A Amino-substituted pyridone derivatives, preparation method and medical application thereof 上海海雁医药科技有限公司 2020-09-25 CN disclosed
WO-2020182018-A1 NITROGEN HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2020-09-17 WO disclosed
EP-3088392-B1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME HEESUNG MAT LTD (KR) 2020-03-11 EP disclosed
US-9728731-B2 Heterocyclic compound and organic light emitting device using same HEESUNG MATERIAL LTD. (KR) 2017-08-08 US disclosed
US-9728731-B2 Heterocyclic compound and organic light emitting device using same HEESUNG MATERIAL LTD. (KR) 2017-08-08 US disclosed
US-9728731-B2 Heterocyclic compound and organic light emitting device using same HEESUNG MATERIAL LTD. (KR) 2017-08-08 US disclosed
US-20160380208-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME HEESUNG MATERIAL LTD. (KR) 2016-12-29 US disclosed
EP-3088392-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME Heesung Material Ltd. (KR) 2016-11-02 EP disclosed
EP-2755973-B1 SUBSTITUTED 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDINES, THEIR USE AS MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM SANOFI SA (FR) 2015-11-04 EP disclosed
CN-104817493-A Aromatic heterocyclic amide substituted diarylurea compound, preparation method and application thereof UNIV XI AN JIAOTONG 2015-08-05 CN disclosed
EP-2808324-A1 PYRROLE COMPOUND Kabushiki Kaisha Yakult Honsha (JP) 2014-12-03 EP disclosed
US-20140343017-A1 PYRROLE COMPOUND KABUSHIKI KAISHA YAKULT HONSHA (JP) 2014-11-20 US disclosed
CN-104080783-A Pyrrole compounds YAKULT HONSHA KK 2014-10-01 CN disclosed
US-4405628-A 4-Pyridylimidazolones and method of use MERRELL DOW PHARMACEUTICALS INC. (US) 1983-09-20 US disclosed
EP-0059948-A1 Novel aroylimidazolones MERRELL DOW PHARMACEUTICALS INC. (US) 1982-09-15 EP disclosed
US-4046768-A 1-Thiazolyl-5-pyridylcarbonyloxyimidazolidinones VELSICOL CHEMICAL CORPORATION (US) 1977-09-06 US disclosed
US-4033753-A HERICIDES VELSICOL CHEMICAL CORPORATION (US) 1977-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343017-A1 PYRROLE COMPOUND TUBB3, TUBB1, TUBB ALDH1A1 2354/4885KDM4E 2403/4885SMN1; SMN2 1580/4885
US-20160380208-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME NOTUM, DDT, CRY1 ALDH1A1 85/4885KDM4E 1977/4885SMN1; SMN2 3944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.